A Phase II, Open-Label, Randomized Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic ER+ /HER2- Breast Cancer Resistant to Aromatase Inhibitor Therapy
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Sep 2017
At a glance
- Drugs GDC 0810 (Primary) ; Fulvestrant
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms HydranGea
- Sponsors Genentech
- 31 Aug 2017 This trial was completed in Spain, according to European Clinical Trials Database record.
- 10 Jun 2017 Biomarkers information updated
- 07 Mar 2017 Planned End Date changed from 1 Mar 2018 to 2 Jan 2018.